How to appeal a UnitedHealthcare treatment-resistant depression — rtms, spravato, ect denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for treatment-resistant depression — rtms, spravato, ect

Cited policy: UnitedHealthcare Commercial Medical Policy: Transcranial Magnetic Stimulation for Major Depression

MDD diagnosis (F32.x / F33.x) — severe or recurrent. Failure of >=4 adequate antidepressant trials (different mechanisms) at therapeutic dose for >=6 wk in current or prior episode, OR intolerance documented; PLUS failed augmentation OR psychotherapy. Standard 30-session course, taper to 36 if response. Reauth requires PHQ-9/MADRS response evidence. Excludes pregnancy, seizure history, intracranial metal.

How UnitedHealthcare denies treatment-resistant depression — rtms, spravato, ect — and how to counter it

Where UnitedHealthcare pushes back: 1) Only 2 antidepressants tried, requires 4; 2) iTBS / SAINT 'experimental'; 3) Maintenance rTMS not covered post-acute.

Counter-arguments that hold up: APA TRD 2022 + STAR*D-DL: TRD = failure of >=2 adequate trials. NeuroStar FDA label (Oct 2008) requires failure of >=1 antidepressant at adequate dose/duration. iTBS FDA-cleared Aug 2018 (NeuroStar TrueAir + MagVenture) — Blumberger THREE-D Lancet 2018 non-inferior to 10 Hz with 50% time savings. SAINT FDA 510(k) cleared Sep 6, 2022 to Magnus Medical (Cole AJP 2022 — 79% remission). Maintenance rTMS — Carpenter 2017 multi-center + Philip 2016 RCT support relapse prevention.

What UnitedHealthcare typically denies for treatment-resistant depression — rtms, spravato, ect

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For treatment-resistant depression — rtms, spravato, ect, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the treatment-resistant depression — rtms, spravato, ect treatments most often flagged for prior auth, step therapy, or medical necessity review:

• NeuroStar rTMS (10 Hz)
• Brainsway Deep TMS
• Magstim Horizon rTMS
• MagVenture rTMS
• iTBS (theta-burst)
• SAINT / SNT accelerated iTBS

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.